Mitsubishi Tanabe Pharma America
Kirstine Belongie PhD is currently serving as the interim Head I&I, senior director, Medical Science at Mitsubishi Tanabe Pharma America, where Kirstine leads the clinical team and strategy for the Immunology & Inflammation portfolio. With a background in biochemistry, diabetes, and embryology, Kirstine has held various leadership roles in the pharmaceutical industry, including at Mitsubishi Tanabe Pharma Development America, G&L Scientific, The Janssen Pharmaceutical Companies of Johnson & Johnson, Merck, and Novo Nordisk. Kirstine's expertise lies in discovering and investigating mechanisms for new diabetes therapies, leading clinical development teams, and organizing recruiting events. Kirstine's research focus includes beta cell therapeutics, islet biology, and diabetes programs.
This person is not in any teams
Mitsubishi Tanabe Pharma America
We are taking on the challenges of complex and debilitating conditions and are committed to meeting the needs of people suffering from serious and often life-threatening illnesses. Today, we are focused on driving scientific discovery in many areas. Our focus remains on bringing treatment to people living with ALS as we strive to make a meaningful difference in their lives. Many people living with amyotrophic lateral sclerosis (ALS) have unmet medical needs. We are committed to doing our best to find solutions that may help address those needs. We continue to expand our work to deepen our understanding of ALS, explore potential biomarkers to aid in further research and seek new answers. Every day we tackle tough challenges in science and medicine. Our teams work diligently to develop smart options that will enable healthcare providers to offer safe and effective treatments for devastating illnesses. Please see our LinkedIn community guidelines here: http://www.mt-pharma-america.com/pdf/LinkedIn-Community-Guidelines.pdf